Business Context and Reporting Period
This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on January 29, 2014. The filing reports the completion of the second closing of a private placement offering (PPO) previously disclosed on January 23, 2014.
Key Financial Metrics
- Gross Proceeds: $6,856,500 raised from the second closing.
- Estimated Fees and Expenses: Approximately $694,000 (placement agent fees and expenses).
- Securities Issued: 6,856,500 Units.
- Unit Composition: One share of Common Stock ($0.001 par value) and one warrant to purchase one share of Common Stock.
- Warrant Terms: Exercise price of $2.00 per share; five-year term.
- Placement Agent Compensation: 10% cash commission of funds raised plus warrants equal to 10% of shares sold (2% for certain named investors) with a $1.00 exercise price.
Material Changes
The primary material change is the issuance of additional equity securities and the receipt of capital. This transaction increases the company's cash position by the net proceeds after deducting fees. The filing does not provide comparative financial data (revenue, profit, or margins) as it is a transactional report rather than a periodic financial statement.
Guidance, Risks, and Contingencies
- Anti-Dilution Protection: Investors in the Units and PPO Warrants have weighted average anti-dilution protection if the Company issues shares for less than $1.00 within 24 months of the final closing.
- Registration Rights: Investors became parties to a Registration Rights Agreement dated January 15, 2014.
- Exemption: The offering was conducted on a "best efforts" basis and exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D, sold only to accredited investors.
- Legal Disclaimer: The filing notes that representations and warranties in the exhibits are for the benefit of the parties to the agreements and may not reflect the actual state of affairs or materiality standards for general investors.
Investor Verification Checklist
- Verify the total aggregate proceeds from the entire PPO (including the first closing on January 23, 2014) to assess total capital raised.
- Review the "best efforts" basis of the offering to understand if the total target amount was fully achieved.
- Confirm the exact number of shares outstanding post-issuance to calculate potential dilution impact.
- Examine the specific terms of the anti-dilution protection to understand future issuance constraints.
- Check subsequent filings for the final closing date and total funds raised.